Although the prognosis of patients with localized prostate cancer is good after surgery, with
a favorable response to androgen deprivation therapy, about one third of them invariably …

Background Despite significant advances in molecular characterization and therapeutic
targeting of advanced prostate cancer, it remains the second most common cause of cancer …

Prostate cancer remains a major cause of cancer-related mortality. Genetic clues to the
molecular pathways driving the most aggressive forms of prostate cancer have been limited …

Loss of function of the PTEN tumour suppressor, resulting in dysregulated activation of the
phosphoinositide 3-kinase (PI3K) signalling network, is recognized as one of the most …

A large number of novel therapeutics is currently undergoing clinical evaluation for the
treatment of prostate cancer, and small molecule signal transduction inhibitors are a …

The tumor suppressor PTEN was originally identified as a negative regulator of the
phosphoinositide 3-kinase (PI3K) signaling, a main regulator of cell growth, metabolism and …

The PI3K signaling pathway is activated in a majority of cancer types. It promotes
tumorigenesis by regulating nutrient metabolism, cell proliferation, survival, migration, and …

In PTEN-mutated tumors, we show that PI3Kα activity is suppressed and PI3K signaling is
driven by PI3Kβ. A selective inhibitor of PI3Kβ inhibits the Akt/mTOR pathway in these …

Purpose PTEN is an essential tumour suppressor gene which encodes a phosphatase
protein that antagonises the PI3K/Akt/mTOR antiapoptotic pathway. Impairment of this …

Loss of PTEN protein results in upregulation of the PI3K/AKT pathway, which appears
dependent on the PI3Kβ isoform. Inhibitors of PI3Kβ have potential to reduce growth of …